Acalabrutinib
Oral, twice daily, indefinitely
Ibrutinib
Oral, once daily, indefinitely
Venetoclax+Obintuzumab
Oral, once daily, 12 months
IV infusion monthly x 6
Chemotherapy + Rituximab
Intravenous, monthly, 6 months
Complete Remission
Normal CBC, No nodes/spleen
Partial Remission
Better CBC + nodes/spleen
Live Longer in Remission
Progression-free survival
Live Longer ± Remission
Overall Survival
Cure
No CLL, Normal life
Rapid Heart Beat
Atrial Fibrillation
Bleeding
Bruising, internal bleeding
High Blood Pressure
Requires treatment
Tumor Lysis
Rapid cell death -> kidney injury
Infections and Transfusions
Decreased blood counts
Low Blood Counts
HARMS
ACCEPTABLE
 HARMS
BENEFITS
 
LEAST IMPORTANT
 
 
MOST IMPORTANT

Harms Salience

All Available Harms
Rapid Heart Beat
Bleeding
High Blood Pressure
Tumor Lysis
Infections and Transfusions
Low Blood Counts
Harms
Likelihood
Severity

Benefits Salience

All Available Benefits
Complete Remission
Partial Remission
Live Longer in Remission
Live Longer ± Remission
Cure
Benefits
Likelihood
Desirability